Over 1 year after phase 3 studies suggested that delgocitinib cream was safe and effective for chronic hand eczema, extension data indicate that control persists without new safety issues.
1. Intravenous ertapenem administered for a mean of 13 weeks for patients with hidradenitis suppurativa was associated with improvement in clinical outcomes, inflammatory markers, and patient satisfaction. 2. Larger prospective and randomized clinical trials are needed to further understand the outcomes and optimal dosing/duration of intravenous ertapenem for hidradenitis suppurativa. Evidence Rating Level: 2 (Good)